Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Australian Patient Treated With DC Bead LUMI™, the First Commercially Available Radiopaque Drug-Eluting Bead PR Newswire LONDON, January 21, 2019 LONDON, January 21, 2019 /PRNewswire/ -- BTG plc...
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims PR Newswire PHILADELPHIA, January 8, 2019 PHILADELPHIA, January 8, 2019 /PRNewswire/ -- Distributed ledger technology is a game...
BTG Announces National Reimbursement for TheraSphere® in France PR Newswire LONDON, December 21, 2018 LONDON, December 21, 2018 /PRNewswire/ -- An estimated 500 patients per year in France could...
BTG Announces Global Launch of the ICEfx™ Cryoablation System PR Newswire LONDON, September 20, 2018 LONDON, September 20, 2018 /PRNewswire/ -- The ICEfx™ Cryoablation system is a compact and...
ELEVATE Study Aims to Improve Selection Criteria and Outcomes for Patients with Severe Emphysema Treated with the PneumRx™ Endobronchial Coil System PR Newswire LONDON, June 11, 2018 LONDON, June...
BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCC Based on experience with 1000 patients over 15 years, the largest single-centre prospective...
New Consensus Guidelines Provide Specific Recommendations for Use of Voraxaze® in Patients with Delayed Methotrexate Clearance PR Newswire LONDON, November 16, 2017 LONDON, November 16, 2017...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
